Vascular BioSciences Opens New Office and Pilot Catheter Manufacturing Facility in Goleta, California

Goleta, Calif., January 8, 2010 – Vascular BioSciences announced today that it has opened a new office and pilot catheter manufacturing facility in Goleta, California. The new Goleta office will also serve as the company’s center for medicinal and computational chemistry.

The Goleta facility will feature an ISO 6 (Class 1,000) clean room for manufacturing the endoarterial biopsy catheter as well as offices and lab space for VBS Pharmaceuticals. This new office is an expansion from the company’s currently established offices in San Diego, California and Durham, North Carolina. Located near the University of California Santa Barbara (UCSB), this new facility will allow for scientific collaboration between Vascular Biosciences, VBS Pharmaceuticals, and distinguished researchers at the University of California Santa Barbara. With VBS Pharmaceuticals’ increasing focus in research and development, the Goleta office’s close proximity to UCSB’s research centers provides a strategic location for the advancement of VBS Pharmaceuticals’ research efforts.

David Mann, CEO and Chairman of Vascular BioSciences and VBS Pharmaceuticals, commented, “The Goleta office will be a great addition to our headquarters in Research Triangle, North Carolina, and provide vital additional research and clean room manufacturing capabilities in California. With a research partnership already established with scientists at the Sanford-Burnham Medical Research Institute at UCSB, the opportunity to work closely with other UCSB faculty will greatly benefit our company’s progress.”

About Vascular BioSciences

Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides disease solutions in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through it’s majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult to treat diseases.